

RECEIVED
CENTRAL FAX CENTER
JUL 27 2006

MARSHALL, GERSTEIN & BORUN LLP
ATTORNEYS AT LAW
6300 SEARS TOWER
233 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606-6357
(312) 474-6300
FAX: (312) 474-0448

07/27/2006

FACSIMILE TRANSMISSION SHEET

TO: United States Patent and
Trademark Office

+1 (571) 273-8300

FROM: Jeanne M. Brashear

RE: Response to Restriction Requirement

PAGES (INCLUDING THIS PAGE): 2

If you do not receive all pages of this fax in good condition, please contact Janis Wilson at (312) 474-6300.

This transmission contains confidential information intended only for the addressee. If you are not the addressee, any disclosure or use of this information by you is strictly prohibited. If you have received this facsimile in error, please notify us by telephone immediately.

RECEIVED
CENTRAL FAX CENTER

JUL 27 2006

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.

Dated: July 27, 2006

Signature: 

(Jeffrey S. Sharp)

Docket No.: 13024/38629A
(PATENT)**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:
John McMichael et al.

Application No.: 10/764,161

Confirmation No.: 8158

Filed: January 23, 2004

Art Unit: 1655

For: METHOD OF TREATMENT OF CONDITIONS BY
ADMINISTRATION OF STREPTOLYSIN O

Examiner: Randall O. Winston

RESPONSE TO RESTRICTION REQUIREMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the restriction requirement set forth in the Office Action mailed June 30, 2006, applicant hereby provisionally elects Group IV (claims 24-32) for continued examination. In accordance with the Office Action, applicant further elects species A drawn to uterine fibrosis. At least claims 24, 25 and 27-32 read on the elected species. Claims 24 appears to be generic.

Applicant's election is made without prejudice. As noted by the examiner, upon the allowance of a generic claim, applicant will be entitled to consideration of claims to not more than a reasonable number of species in addition to the elected species, provided that all claims to each additional species are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.146.

Dated: July 27, 2006

Respectfully submitted,

By 
Jeffrey S. Sharp

Registration No.: 31,879

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicants